EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes

Tae Seop Lim iD, Ho Soo Chun iD, Soon Sun Kim iD, Ja Kyung Kim iD, Minjong Lee iD, Hyo Jung Cho iD, Seung Up Kim iD, Jae Youn Cheong iD

Gut and Liver · 15.07.2023 · 17 (4) · 610-619

DOI: 10.5009/gnl220400 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 17.02.2023. Verfasst von Tae Seop Lim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is categorized into three subtypes: overweight/obese (OW), lean/normal weight with metabolic abnormalities, and diabetes mellitus (DM). We investigated whether fibrotic burden in liver differs across subtypes of MAFLD patients.

Methods

This cross-sectional multicenter study was done in cohorts of subjects who underwent a comprehensive medical health checkup between January 2014 and December 2020. A total of 42,651 patients with ultrasound-diagnosed fatty liver were included. Patients were classified as no MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. Advanced liver fibrosis was defined based on the nonalcoholic fatty liver disease fibrosis score (NFS) or fibrosis-4 (FIB-4) index.

Results

The mean age of the patients was 50.0 years, and 74.1% were male. The proportion of patients with NFS-defined advanced liver fibrosis was the highest in DM-MAFLD (6.6%), followed by OW-MAFLD (2.0%), lean-MAFLD (1.3%), and no MAFLD (0.2%). The proportion of patients with FIB-4-defined advanced liver fibrosis was the highest in DM-MAFLD (8.6%), followed by lean-MAFLD (3.9%), OW-MAFLD (3.0%), and no MAFLD (2.0%). With the no MAFLD group as reference, the adjusted odds ratios (95% confidence intervals) for NFS-defined advanced liver fibrosis were 4.46 (2.09 to 9.51), 2.81 (1.12 to 6.39), and 9.52 (4.46 to 20.36) in OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively, and the adjusted odds ratios for FIB-4-defined advanced liver fibrosis were 1.03 (0.78 to 1.36), 1.14 (0.82 to 1.57), and 1.97 (1.48 to 2.62) in OW-MAFLD, lean-MAFLD, and DM-MAFLD.

Conclusions

Fibrotic burden in the liver differs across MAFLD subtypes. Optimized surveillance strategies and therapeutic options might be needed for different MAFLD subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansMaleMiddle AgedFemaleCross-Sectional StudiesLiver CirrhosisObesity

Stichwörter der Autor:innen

Liver fibrosisMetabolic dysfunction-associated fatty liver diseaseNon-alcoholic fatty liver diseaseSubtype

Autor:innen und Institutionen

  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Yongin Severance Hospital, Yongin, Korea.
  • Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Ewha Womans University Medical Center, Seoul, Korea.
  • Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
  • Yonsei Liver Center, Severance Hospital, Seoul, Korea.

ORCID-Profile: Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong

Förderung

  • Ministry of Health and Welfare
  • Korea Health Industry Development Institute

Zitieren

APA

Lim, T. S., Chun, H. S., Kim, S. S., Kim, J. K., Lee, M., Cho, H. J., Kim, S. U., & Cheong, J. Y. (2023). Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. Gut and Liver, 17(4), 610-619. https://doi.org/10.5009/gnl220400

Vancouver

Lim TS, Chun HS, Kim SS, Kim JK, Lee M, Cho HJ, et al. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. Gut and Liver. 2023;17(4):610-619. doi:10.5009/gnl220400

BibTeX
@article{Lim2023,
  author = {Lim, Tae Seop and Chun, Ho Soo and Kim, Soon Sun and Kim, Ja Kyung and Lee, Minjong and Cho, Hyo Jung and Kim, Seung Up and Cheong, Jae Youn},
  title = {Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes},
  journal = {Gut and Liver},
  year = {2023},
  volume = {17},
  number = {4},
  pages = {610--619},
  doi = {10.5009/gnl220400}
}
Kostenlos starten →